Disclosures for "Remibrutinib Inhibits Neuroinflammation Driven by B Cells and Myeloid Cells in Preclinical Models of Multiple Sclerosis")
-
Bernd C. Kieseier, MD has nothing to disclose.
-
Mr. Cenni has received personal compensation for serving as an employee of Novartis.
-
Dr. Nuesslein-Hildesheim has received personal compensation for serving as an employee of Novartis Pharma AG. Dr. Nuesslein-Hildesheim has stock in Novartis Pharma AG.
-
Dr. Ferrero has received personal compensation for serving as an employee of Novartis.
-
Catherine Huck has received personal compensation for serving as an employee of Novartis.
-
Mr. Eichlisberger has nothing to disclose.
-
Dr. Ziehn has received personal compensation for serving as an employee of Novartis AG.